Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer

Por Pal, Sumanta Kumar, Sartor, Oliver
Publicado em 2010

Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer

Por Pal, Sumanta Kumar, Sartor, Oliver
Publicado em 2011

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors

Por Pal, Sumanta Kumar, Figlin, Robert A.
Publicado em 2010

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

Por Pal, Sumanta Kumar, Figlin, Robert A.
Publicado em 2011

A “Game of Thrones” in Metastatic Renal Cell Carcinoma: Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors and Mammalian Target of Rapamycin Inhibitors Battling for Posi...

Por Pal, Sumanta Kumar, Vogelzang, Nicholas J.
Publicado em 2012

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?

Por Chehrazi-Raffle, Alexander, Pal, Sumanta Kumar
Publicado no EBioMedicine (2020)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Por Pal, Sumanta Kumar, Twardowski, Przemyslaw, Sartor, Oliver
Publicado em 2010

Deciphering the anticancer mechanisms of sunitinib

Por Pal, Sumanta Kumar, Figlin, Robert A, Yu, Hua
Publicado em 2010

Triple negative breast cancer: unmet medical needs

Por Pal, Sumanta Kumar, Childs, Barrett H., Pegram, Mark
Publicado em 2010

Targeted Therapies for Non-Small Lung Cancer: An Evolving Landscape

Por Pal, Sumanta Kumar, Figlin, Robert A., Reckamp, Karen
Publicado em 2010

Cognitive changes associated with endocrine therapy for breast cancer

Por Agrawal, Kunal, Onami, Susan, Mortimer, Joanne E., Pal, Sumanta Kumar
Publicado em 2010

Male breast cancer: An update in diagnosis, treatment and molecular profiling

Por Onami, Susan, Ozaki, Melanie, Mortimer, Joanne E., Pal, Sumanta Kumar
Publicado em 2010

Breaking through a plateau in renal cell carcinoma therapeutics: Development and incorporation of biomarkers

Por Pal, Sumanta Kumar, Kortylewski, Marcin, Yu, Hua, Figlin, Robert A.
Publicado em 2010

Oncologists’ recommendations for adjuvant endocrine therapy in older adults of varying health states

Por Naeim, Arash, Wong, F. Lennie, Pal, Sumanta Kumar, Hurria, Arti
Publicado em 2010

Current clinical challenges in prostate cancer

Por Silberstein, Jonathan L., Pal, Sumanta Kumar, Lewis, Brian, Sartor, Oliver
Publicado no Transl Androl Urol (2013)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma

Por Maia, Manuel Caitano, Dizman, Nazli, Salgia, Meghan, Pal, Sumanta Kumar
Publicado no Kidney Cancer (2017)

Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma

Por Staehler, Michael, Battle, Dena, Pal, Sumanta Kumar, Bergerot, Cristiane Decat
Publicado no Eur Urol Focus (2021)

Overcoming Chemotherapy Resistance in Prostate Cancer

Por Madan, Ravi A., Pal, Sumanta Kumar, Sartor, Oliver, Dahut, William L.
Publicado no Clin Cancer Res (2011)

STAT3: A Target to Enhance Antitumor Immune Response

Por Lee, Heehyoung, Pal, Sumanta Kumar, Reckamp, Karen, Figlin, Robert A., Yu, Hua
Publicado em 2011

Recent advances in the therapy of castration-resistant prostate cancer: The price of progress

Por Vasani, Dhwanishiva, Josephson, David Y., Carmichael, Courtney, Sartor, Oliver, Pal, Sumanta Kumar
Publicado em 2011